Participated · Series A · Aug 2026

Remepy develops Hybrid Drugs that integrate prescription medicines with personalized, AI-driven therapeutic apps to combine pharmacology with adaptive physical, cognitive, and behavioral interventions. The company partners with pharmaceutical firms to co-develop these drug–software combination products and recently announced a strategic collaboration with Merck KGaA. Remepy’s lead program, Hybridopa for Parkinson’s disease, produced encouraging Phase IIa results supported by peer‑reviewed publications and is being prepared for a global Phase III trial expected to begin in Q4 2026. The Series A financing and existing investor base have brought total capital raised to $62 million, providing funds to expand the company’s pipeline, platform, and pharmaceutical partnerships. Remepy positions its approach within emerging FDA frameworks for drug‑software combination products and aims to create new IP and lifecycle-management opportunities for partner drugs.

Participated · Seed · Oct 2025

Aerska is developing delivery technologies intended to enable systemic delivery of RNA medicines to the brain to treat serious neurological diseases. The company is focused on improving selectivity of RNAi payload delivery and on approaches that could target multiple disease pathways simultaneously. Aerska announced an additional $10M investment from GHIC as part of its Series A, indicating ongoing Series A financing activity. The company positions the GHIC investment as a partnership to advance its platform toward clinical or translational goals. No public operating metrics or founding date were disclosed in the announcement.

Participated · Seed · Nov 2024

Jimini Health builds clinician-supervised AI infrastructure for behavioral health provider organizations, with a flagship platform called Sage that integrates into regulated clinical environments. Sage is designed so licensed clinicians maintain oversight of every patient interaction while enabling providers to deploy AI at scale. The company emphasizes compliance with regulatory requirements and direct integration with clinical workflows. Jimini plans to expand AI development across additional clinical settings and scale partnerships with large behavioral health providers nationwide using proceeds from its recent financing. Financially, the company raised a $17M Seed round led by M13, bringing total funding to over $25M. Jimini Health is based in New York and is led by CEO Luis Voloch.

Participated · Seed · Sep 2024

Neurode produces a wearable headband that uses light electrical stimulation over the prefrontal cortex to treat ADHD symptoms and light-based sensing to monitor changes in brain activity. The device is designed for daily 20-minute use and is currently available through a private beta. Co-founder Nathalie Gouailhardou is a neuroscientist who was diagnosed with ADHD and developed the idea while working with fNIRS brain-imaging equipment; she co-founded the company with Damian Sofrevski. The company was founded in 2021 and filed patents for its device that year. Neurode has raised $3.5 million in pre-seed funding to support clinical trials and early development. Management says the goal is to pursue FDA approval for the device, though no timeline has been provided. The company may expand its wearable technology to other conditions such as age-related cognitive decline and depression in the future.

Participated · Equity · Aug 2024

Ancilia Biosciences develops virus-resistant live bacterial products for human health and other applications using proprietary CRISPR-based technologies. Its CoVE™ platform identifies and characterizes viral phages, and its EPIC platform leverages bacteria’s natural CRISPR function to produce live biotherapeutics and microbial products with immunity to key viral pathogens. The company has achieved proof-of-concept and holds key patents protecting these inventions. Led by CEO Alexandra Sakatos and co-founded by Dr. Rodolphe Barrangou and David Paez-Espino, the team combines expertise in CRISPR, virology, and bioinformatics. Ancilia intends to use the $4.2M financing to expand operations and its R&D sector. The company is based in New York City.